| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 11 | 2018 | 31 | 3.140 |
Why?
|
| Biomarkers, Tumor | 12 | 2015 | 198 | 2.850 |
Why?
|
| Rectal Neoplasms | 6 | 2015 | 15 | 2.330 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2015 | 17 | 2.200 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 100 | 1.930 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 536 | 1.800 |
Why?
|
| Decision Support Techniques | 2 | 2023 | 39 | 1.410 |
Why?
|
| Smoking | 5 | 2023 | 160 | 1.390 |
Why?
|
| Chemoradiotherapy | 5 | 2015 | 55 | 1.180 |
Why?
|
| Aged | 22 | 2021 | 7415 | 1.000 |
Why?
|
| Prognosis | 13 | 2015 | 727 | 0.920 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 573 | 0.890 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2018 | 111 | 0.880 |
Why?
|
| Disease-Free Survival | 10 | 2015 | 169 | 0.870 |
Why?
|
| Urologic Neoplasms | 2 | 2015 | 4 | 0.860 |
Why?
|
| Humans | 39 | 2023 | 22838 | 0.820 |
Why?
|
| Smokers | 2 | 2023 | 10 | 0.810 |
Why?
|
| Male | 27 | 2020 | 12415 | 0.800 |
Why?
|
| Galectin 1 | 3 | 2018 | 3 | 0.800 |
Why?
|
| Kidney Neoplasms | 2 | 2015 | 75 | 0.800 |
Why?
|
| Culturally Competent Care | 1 | 2023 | 8 | 0.780 |
Why?
|
| Female | 28 | 2020 | 12901 | 0.780 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 6 | 0.700 |
Why?
|
| Middle Aged | 20 | 2018 | 7869 | 0.660 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 71 | 0.610 |
Why?
|
| Immunohistochemistry | 9 | 2015 | 334 | 0.590 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 145 | 0.590 |
Why?
|
| Attitude to Health | 1 | 2019 | 90 | 0.580 |
Why?
|
| Gene Amplification | 2 | 2015 | 21 | 0.570 |
Why?
|
| Urinary Bladder | 1 | 2018 | 18 | 0.560 |
Why?
|
| Health Status | 1 | 2019 | 200 | 0.560 |
Why?
|
| Mass Screening | 1 | 2018 | 160 | 0.520 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 34 | 0.520 |
Why?
|
| Survivors | 1 | 2017 | 69 | 0.510 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 133 | 0.510 |
Why?
|
| Quality of Life | 2 | 2019 | 554 | 0.500 |
Why?
|
| Communication | 1 | 2017 | 96 | 0.490 |
Why?
|
| Cell Movement | 2 | 2016 | 77 | 0.490 |
Why?
|
| Bisexuality | 2 | 2015 | 7 | 0.480 |
Why?
|
| Homosexuality, Female | 2 | 2015 | 7 | 0.480 |
Why?
|
| Signal Transduction | 1 | 2018 | 398 | 0.480 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2015 | 1 | 0.480 |
Why?
|
| Transaminases | 1 | 2015 | 6 | 0.470 |
Why?
|
| Neoadjuvant Therapy | 5 | 2015 | 61 | 0.470 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2015 | 1 | 0.460 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2015 | 1 | 0.460 |
Why?
|
| Lipogenesis | 1 | 2015 | 1 | 0.460 |
Why?
|
| Urinary Tract | 1 | 2015 | 2 | 0.460 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 4 | 0.460 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2015 | 1 | 0.450 |
Why?
|
| Group II Phospholipases A2 | 1 | 2015 | 1 | 0.450 |
Why?
|
| Ureteral Neoplasms | 1 | 2015 | 5 | 0.450 |
Why?
|
| Repressor Proteins | 1 | 2015 | 33 | 0.450 |
Why?
|
| Lipids | 1 | 2015 | 45 | 0.450 |
Why?
|
| Kidney Pelvis | 1 | 2015 | 12 | 0.450 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 1 | 0.440 |
Why?
|
| Cognition | 1 | 2021 | 948 | 0.440 |
Why?
|
| Neoplasms | 1 | 2017 | 216 | 0.440 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 50 | 0.440 |
Why?
|
| Adult | 14 | 2019 | 6892 | 0.430 |
Why?
|
| Quality of Health Care | 1 | 2015 | 89 | 0.420 |
Why?
|
| Disease Progression | 6 | 2015 | 528 | 0.400 |
Why?
|
| ELAV Proteins | 1 | 2012 | 1 | 0.390 |
Why?
|
| Cyclin A | 1 | 2012 | 4 | 0.390 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2013 | 21 | 0.390 |
Why?
|
| Cytoplasm | 1 | 2012 | 33 | 0.390 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 3718 | 0.360 |
Why?
|
| Urothelium | 3 | 2018 | 5 | 0.350 |
Why?
|
| Smoking Cessation | 3 | 2019 | 37 | 0.350 |
Why?
|
| United States | 5 | 2023 | 1758 | 0.340 |
Why?
|
| Risk Factors | 5 | 2021 | 1966 | 0.320 |
Why?
|
| Annexin A1 | 1 | 2010 | 1 | 0.320 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 244 | 0.310 |
Why?
|
| Carcinoma | 3 | 2018 | 65 | 0.300 |
Why?
|
| Proteomics | 3 | 2018 | 58 | 0.300 |
Why?
|
| Chicago | 4 | 2019 | 812 | 0.290 |
Why?
|
| Blotting, Western | 4 | 2015 | 131 | 0.280 |
Why?
|
| Sexual and Gender Minorities | 2 | 2019 | 22 | 0.270 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 284 | 0.270 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 758 | 0.260 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 37 | 0.260 |
Why?
|
| Tobacco Use Disorder | 2 | 2019 | 15 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 166 | 0.240 |
Why?
|
| Minority Groups | 3 | 2015 | 66 | 0.240 |
Why?
|
| Taiwan | 4 | 2018 | 5 | 0.240 |
Why?
|
| Histones | 2 | 2015 | 28 | 0.220 |
Why?
|
| Survival Rate | 4 | 2014 | 316 | 0.210 |
Why?
|
| Smoking Prevention | 2 | 2014 | 17 | 0.210 |
Why?
|
| Health Surveys | 2 | 2021 | 77 | 0.200 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 12 | 0.200 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2015 | 4 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2019 | 2929 | 0.190 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 101 | 0.190 |
Why?
|
| Internet | 1 | 2023 | 76 | 0.190 |
Why?
|
| Psychometrics | 1 | 2023 | 176 | 0.190 |
Why?
|
| Attitude of Health Personnel | 1 | 2023 | 133 | 0.180 |
Why?
|
| Body Mass Index | 2 | 2021 | 377 | 0.180 |
Why?
|
| Physicians | 1 | 2023 | 105 | 0.170 |
Why?
|
| Violence | 1 | 2021 | 35 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 41 | 0.170 |
Why?
|
| Health Behavior | 2 | 2019 | 134 | 0.170 |
Why?
|
| Odds Ratio | 2 | 2018 | 219 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2019 | 51 | 0.150 |
Why?
|
| Age Distribution | 1 | 2019 | 67 | 0.150 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1013 | 0.150 |
Why?
|
| Advisory Committees | 1 | 2018 | 15 | 0.150 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 31 | 0.150 |
Why?
|
| Decision Making | 1 | 2020 | 176 | 0.140 |
Why?
|
| Apoptosis | 2 | 2018 | 195 | 0.140 |
Why?
|
| Educational Status | 1 | 2019 | 209 | 0.140 |
Why?
|
| Lythraceae | 1 | 2018 | 1 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2016 | 163 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 36 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 9 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2018 | 13 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 439 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 49 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1045 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2015 | 144 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2017 | 34 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2015 | 284 | 0.130 |
Why?
|
| Economics, Hospital | 1 | 2017 | 5 | 0.130 |
Why?
|
| Age Factors | 1 | 2019 | 636 | 0.130 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 19 | 0.130 |
Why?
|
| Medicaid | 1 | 2017 | 36 | 0.130 |
Why?
|
| Sexuality | 2 | 2014 | 14 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 13 | 0.130 |
Why?
|
| Medicare | 1 | 2017 | 105 | 0.130 |
Why?
|
| Transgender Persons | 2 | 2014 | 19 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 35 | 0.120 |
Why?
|
| Leadership | 1 | 2017 | 78 | 0.120 |
Why?
|
| Gene Expression | 2 | 2016 | 178 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 441 | 0.120 |
Why?
|
| Laser Capture Microdissection | 1 | 2015 | 1 | 0.120 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 19 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 125 | 0.120 |
Why?
|
| Young Adult | 3 | 2015 | 1645 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 85 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 85 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 132 | 0.120 |
Why?
|
| Hyaluronan Synthases | 1 | 2015 | 4 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 86 | 0.110 |
Why?
|
| Social Discrimination | 1 | 2015 | 5 | 0.110 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 15 | 0.110 |
Why?
|
| Independent Living | 1 | 2017 | 225 | 0.110 |
Why?
|
| Professional-Patient Relations | 1 | 2015 | 28 | 0.110 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2014 | 1 | 0.110 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 2014 | 1 | 0.110 |
Why?
|
| Endosonography | 1 | 2014 | 10 | 0.110 |
Why?
|
| Fluorouracil | 1 | 2014 | 46 | 0.110 |
Why?
|
| Social Marketing | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2014 | 1408 | 0.110 |
Why?
|
| Acculturation | 1 | 2014 | 22 | 0.110 |
Why?
|
| Mass Media | 1 | 2014 | 10 | 0.110 |
Why?
|
| Awareness | 1 | 2014 | 37 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2014 | 46 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 200 | 0.100 |
Why?
|
| Obesity | 1 | 2016 | 289 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 87 | 0.100 |
Why?
|
| Health Promotion | 1 | 2014 | 123 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 110 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2012 | 22 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 121 | 0.090 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2011 | 6 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 73 | 0.090 |
Why?
|
| 14-3-3 Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Mouth Neoplasms | 1 | 2011 | 19 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2014 | 354 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2011 | 41 | 0.080 |
Why?
|
| Thrombolytic Therapy | 1 | 2011 | 44 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 58 | 0.080 |
Why?
|
| Casein Kinase II | 1 | 2010 | 2 | 0.080 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 102 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2010 | 2 | 0.080 |
Why?
|
| Cystectomy | 1 | 2010 | 8 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 158 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2010 | 32 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2009 | 4 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 7 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 16 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2009 | 30 | 0.070 |
Why?
|
| Stromal Cells | 2 | 2009 | 33 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 102 | 0.070 |
Why?
|
| Dementia | 1 | 2011 | 388 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 273 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 15 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 255 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2004 | 23 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 349 | 0.050 |
Why?
|
| Cultural Characteristics | 1 | 2019 | 19 | 0.040 |
Why?
|
| Risk | 2 | 2011 | 162 | 0.040 |
Why?
|
| Adolescent | 2 | 2014 | 1875 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2019 | 85 | 0.040 |
Why?
|
| Plants, Medicinal | 1 | 2018 | 2 | 0.040 |
Why?
|
| Solvents | 1 | 2018 | 3 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 25 | 0.040 |
Why?
|
| Acetates | 1 | 2018 | 16 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 23 | 0.040 |
Why?
|
| Fruit | 1 | 2018 | 24 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 21 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2018 | 11 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 95 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 315 | 0.030 |
Why?
|
| Investments | 1 | 2017 | 5 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 58 | 0.030 |
Why?
|
| Chromosomes, Human | 2 | 2009 | 6 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2009 | 24 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 23 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 36 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 99 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 76 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 156 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 78 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 165 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 1490 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 1259 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2016 | 206 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 16 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 24 | 0.030 |
Why?
|
| Racism | 1 | 2014 | 24 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2014 | 113 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 228 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 56 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 17 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 124 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 50 | 0.020 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 2011 | 2 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 24 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 103 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 3311 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 1407 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 215 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 138 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 128 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2011 | 61 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 544 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 480 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 227 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 15 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 241 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 800 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2012 | 2966 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2004 | 6 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 9 | 0.010 |
Why?
|